Table 3.
Treatment results by systemic chemotherapy and chemoradiotherapy
| No. | Sex | Age | Stage | PS | EGFR mutation status | Initial treatment | OR | PFS (mos) | OS (mos) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 55 | Relapsed | 1 | Wild | DTX | PD | 0.7 | 7.3 | Died |
| 2 | F | 69 | Relapsed | 1 | Exon 19 del | Gefitinib | CR | 35.1 | 53.9 | Died |
| 3 | M | 60 | Relapsed | 1 | Wild | CBDCA + PTX | PD | 0.9 | 3.7 | Died |
| 4 | F | 45 | Relapsed | 0 | Wild | Gefitinib | PD | 1.7 | 10.7 | Died |
| 5 | M | 63 | Relapsed | 1 | Wild | CBDCA + PTX | PD | 0.6 | 12.7 | Died |
| 6 | M | 62 | Relapsed | 1 | Wild | CDDP + GEM | PD | 2.5 | 18.7 | Died |
| 7 | F | 53 | Relapsed | 2 | Wild | CBDCA + PTX | PD | 0.4 | 1 | Died |
| 8 | F | 55 | Relapsed | 1 | Wild | DTX | PD | 0.7 | 1.4 | Died |
| 9 | M | 56 | Advanced | 1 | NA | CBDCA + PTX | PD | 0.6 | 1.0 | Died |
| 10 | M | 77 | Advanced | 2 | Wild | CBDCA + ETP | PD | 1.5 | 7.2 | Died |
| 11 | M | 43 | Advanced | 1 | Wild | CBDCA + PTX | SD | 4.5 | 10.3 | Died |
| 12 | M | 62 | Advanced | 2 | Wild | CBDCA + PTX | NE | 0.4 | 0.4 | Died |
| 13 | M | 56 | Relapsed | 0 | Wild | CDDP + GEM | NE | 109.2 | 109.2 | Alive |
| 14 | M | 65 | Stage IIIA | 1 | Wild | CDDP + VNR + TRT | PR | 5.0 | 6.6 | Died |
| 15 | F | 66 | Relapsed | 1 | Exon 21 L858R | CDDP + VNR + TRT | PR | 3.9 | 6.9 | Died |
| 16 | F | 66 | Stage IIIA | 0 | NA | CDDP + VNR + TRT | PR | 65.4 | 65.4 | Alive |
PS performance status, OR overall response, PFS progression-free survival, OS overall survival, DTX docetaxel, CBDCA carboplatin, PTX paclitaxel, CDDP cisplatin, GEM gemcitabine, ETP etoposide, VNR vinorelbine, TRT thoracic radiotherapy, SD stable disease, CR complete response, PD progressive disease, NE not evaluable, PR partial response